SGEN - Why Is US Pharma Giant Pfizer Stock Trading Lower Today? | Benzinga
Pfizer Inc (NYSE: PFE) provided its full-year 2024 guidance, which includes the expected financial impact from the Seagen Inc (NASDAQ: SGEN) transaction.
On Tuesday, Pfizer said it received all regulatory approvals to close the deal on Thursday, about nine months after announcing the acquisition.
For FY24, the pharma giant expects revenue of $58.5 billion-$61.5 billion, including the expected contribution from the Seagen acquisition versus the consensus of $63.17 billion.
The company anticipates approximately $8 billion in revenues for its COVID-19 products, Comirnaty and Paxlovid. ...